Johnson & Johnson | 10-Q: Q2 2025 Earnings Report

Johnson & Johnson reported Q2 2025 worldwide sales of $23.7 billion, representing a 5.8% increase year-over-year, with operational growth of 4.6% and a currency impact of 1.2%. The Innovative Medicine segment grew 4.9% to $15.2 billion, while MedTech increased 7.3% to $8.5 billion. Net earnings rose to $5.5 billion, with earnings per share of $2.29.The company reversed approximately $7 billion of previously accrued talc reserves in Q2 following the Texas Bankruptcy Court's dismissal of the Red River case. This significantly impacted the quarter's financial results, with consolidated earnings before tax reaching $6.5 billion or 27.3% of sales compared to $5.7 billion or 25.6% in Q2 2024.Looking ahead, J&J faces challenges including STELARA biosimilar competition, which negatively impacted worldwide operational sales by 7.1% in Q2. The company completed strategic acquisitions including Intra-Cellular Therapies for $14.5 billion and maintained strong operational performance across key franchises like DARZALEX and TREMFYA. The Board declared a quarterly dividend of $1.30 per share.

Johnson & Johnson reported Q2 2025 worldwide sales of $23.7 billion, representing a 5.8% increase year-over-year, with operational growth of 4.6% and a currency impact of 1.2%. The Innovative Medicine segment grew 4.9% to $15.2 billion, while MedTech increased 7.3% to $8.5 billion. Net earnings rose to $5.5 billion, with earnings per share of $2.29.The company reversed approximately $7 billion of previously accrued talc reserves in Q2 following the Texas Bankruptcy Court's dismissal of the Red River case. This significantly impacted the quarter's financial results, with consolidated earnings before tax reaching $6.5 billion or 27.3% of sales compared to $5.7 billion or 25.6% in Q2 2024.Looking ahead, J&J faces challenges including STELARA biosimilar competition, which negatively impacted worldwide operational sales by 7.1% in Q2. The company completed strategic acquisitions including Intra-Cellular Therapies for $14.5 billion and maintained strong operational performance across key franchises like DARZALEX and TREMFYA. The Board declared a quarterly dividend of $1.30 per share.